Science Advances

Supplementary Materials

This PDF file includes:

  • Fig. S1. Stable heterologous expression of TRPV1 in selected cell lines.
  • Fig. S2. RTX-enhanced TRPV1-mediated uptake of gentamicin is attenuated by extracellular Ca2+.
  • Fig. S3. Viability of cell lines incubated with a TRPV1 agonist or antagonist.
  • Fig. S4. Agonists and antagonists of TRPV1 do not affect the bactericidal efficacy of aminoglycosides.
  • Fig. S5. LPS enhanced TRPV1 expression in renal cells in vivo.
  • Fig. S6. LPS did not enhance strial uptake of GTTR in Trpv1 KO mice in vivo.
  • Fig. S7. LPS exacerbates kanamycin-induced hearing loss in wild-type, but not in Trpv1+/− or Trpv1 KO, mice.
  • Fig. S8. LPS increases cochlear (but not serum) levels of gentamicin.
  • Fig. S9. LPS exacerbates kanamycin-induced OHC loss in wild-type, but not in Trpv1+/− or Trpv1 KO, mice.
  • Fig. S10. TRPV1 immunolabeling in cochlear tissues from wild-type and Trpv1 KO mice.
  • Table S1. Significant differences in threshold at 3 weeks after treatment from baseline for wild-type (C57) mice.
  • Table S2. Significant differences in threshold at 3 weeks after treatment from baseline for Trpv1+/− mice.
  • Table S3. Significant differences in threshold at 3 weeks after treatment from baseline for Trpv1 KO mice.
  • Table S4. Significant differences in thresholds between strains at 3 weeks after treatment with DPBS only.
  • Table S5. Significant differences in thresholds between strains at 3 weeks after treatment with LPS only.
  • Table S6. Significant differences in thresholds between strains at 3 weeks after treatment with kanamycin only.
  • Table S7. Significant differences in thresholds between strains at 3 weeks after treatment with LPS + kanamycin.
  • Table S8. Significant differences in thresholds between treatment groups at 3 weeks after treatment for wild-type (C57) mice.
  • Table S9. Significant differences in thresholds between treatment groups at 3 weeks after treatment for Trpv1+/− mice.
  • Table S10. Significant differences in thresholds between treatment groups at 3 weeks after treatment for Trpv1 KO mice.

Download PDF

Files in this Data Supplement: